Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Cervical cancer remains a significant global health concern, driving the need for novel antitumor agents.
• Erlotinib is a targeted therapy, but resistance and side effects necessitate exploration of new drug candidates.
• 1,2,3-triazole derivatives have shown promise in various therapeutic areas, including anticancer applications.

Purpose of the Study:

• To design, synthesize, and evaluate novel erlotinib-linked 1,2,3-triazole compounds for their antitumor activity against human cervical cancer.
• To identify specific compounds with potent inhibitory effects on cervical cancer cell lines.
• To investigate the mechanism of action, including apoptosis induction, cell cycle arrest, and EGFR inhibition.

Main Methods:

• Synthesis of 14 erlotinib-linked 1,2,3-triazole compounds.
• Structural confirmation using 1H NMR, 13C NMR, and high-resolution mass spectrometry (HR MS).
• In vitro antitumor activity assays against human cervical cancer HeLa cells, including IC50 determination, apoptosis assays, cell cycle analysis, colony formation assays, and epidermal growth factor receptor (EGFR) inhibition assays.

Main Results:

• Six synthesized compounds demonstrated significant inhibitory activity against HeLa cells.
• Compound 4m exhibited the highest potency with an IC50 of 3.79 μM.
• Compounds 4d, 4k, and 4l induced apoptosis and cell cycle arrest, with 4d and 4l also inhibiting colony formation and EGFR.

Conclusions:

• Erlotinib-linked 1,2,3-triazole compounds represent a promising class of novel anticancer agents against cervical cancer.
• Compounds 4d, 4k, and 4l warrant further investigation due to their potent cytotoxic effects, ability to induce apoptosis and cell cycle arrest, and EGFR inhibitory activity.
• These findings support the potential of these compounds as effective therapeutic candidates for cervical cancer treatment.